Who are Nicotine polacrilex, Bupropion's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicotine-polacrilex-bupropion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nicotine polacrilex, Bupropion — Competitive Intelligence Brief

Nicotine polacrilex, Bupropion (Nicotine polacrilex, Bupropion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy combined with antidepressant. Area: Addiction Medicine / Smoking Cessation.

phase 3 Nicotine replacement therapy combined with antidepressant Nicotinic acetylcholine receptors (nicotine polacrilex); norepinephrine and dopamine transporters (bupropion) Addiction Medicine / Smoking Cessation Small molecule Live · refreshed every 30 min

Target snapshot

Nicotine polacrilex, Bupropion (Nicotine polacrilex, Bupropion) — University of California, San Francisco. Nicotine polacrilex provides nicotine replacement while bupropion inhibits norepinephrine and dopamine reuptake to reduce cravings and withdrawal symptoms during smoking cessation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine polacrilex, Bupropion TARGET	Nicotine polacrilex, Bupropion	University of California, San Francisco	phase 3	Nicotine replacement therapy combined with antidepressant	Nicotinic acetylcholine receptors (nicotine polacrilex); norepinephrine and dopamine transporters (bupropion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy combined with antidepressant class)

University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nicotine polacrilex, Bupropion — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotine-polacrilex-bupropion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab